EE05433B1 - 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine - Google Patents

4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine

Info

Publication number
EE05433B1
EE05433B1 EEP200300435A EEP200300435A EE05433B1 EE 05433 B1 EE05433 B1 EE 05433B1 EE P200300435 A EEP200300435 A EE P200300435A EE P200300435 A EEP200300435 A EE P200300435A EE 05433 B1 EE05433 B1 EE 05433B1
Authority
EE
Estonia
Prior art keywords
pharmaceutically acceptable
rasolo
methoxypyrid
butylamino
triazine
Prior art date
Application number
EEP200300435A
Other languages
English (en)
Inventor
J. Gilligan Paul
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of EE200300435A publication Critical patent/EE200300435A/et
Publication of EE05433B1 publication Critical patent/EE05433B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
EEP200300435A 2001-03-13 2002-03-06 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine EE05433B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27540301P 2001-03-13 2001-03-13
PCT/US2002/006837 WO2002072202A1 (en) 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Publications (2)

Publication Number Publication Date
EE200300435A EE200300435A (et) 2003-12-15
EE05433B1 true EE05433B1 (et) 2011-06-15

Family

ID=23052141

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300435A EE05433B1 (et) 2001-03-13 2002-03-06 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine

Country Status (35)

Country Link
US (4) US20030125330A1 (et)
EP (1) EP1368094B1 (et)
JP (1) JP4549630B2 (et)
KR (1) KR100875595B1 (et)
CN (1) CN100427093C (et)
AR (1) AR032986A1 (et)
AT (1) ATE355102T1 (et)
AU (1) AU2002245605B2 (et)
BG (1) BG66331B1 (et)
BR (1) BR0208357A (et)
CA (1) CA2440553C (et)
CY (1) CY1106607T1 (et)
CZ (1) CZ20032481A3 (et)
DE (1) DE60218434T2 (et)
DK (1) DK1368094T3 (et)
EE (1) EE05433B1 (et)
ES (1) ES2282401T3 (et)
GE (1) GEP20053608B (et)
HR (1) HRP20030822B1 (et)
HU (1) HU229317B1 (et)
IL (2) IL157615A0 (et)
IS (1) IS2839B (et)
MX (1) MXPA03008185A (et)
MY (1) MY146935A (et)
NO (1) NO328580B1 (et)
NZ (1) NZ528207A (et)
PL (1) PL208278B1 (et)
PT (1) PT1368094E (et)
RS (1) RS50863B (et)
RU (1) RU2292347C2 (et)
SK (1) SK287603B6 (et)
TW (1) TWI257388B (et)
UA (1) UA74634C2 (et)
WO (1) WO2002072202A1 (et)
ZA (1) ZA200306995B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094782B1 (en) * 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
NZ528207A (en) * 2001-03-13 2006-02-24 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7041671B2 (en) * 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
EP1615929A1 (en) * 2003-04-15 2006-01-18 Pharmacia & Upjohn Company LLC Pyrrolo [1,2-b] pyridazine compounds and their uses
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en) * 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US20150094310A1 (en) * 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR102079844B1 (ko) 2016-09-20 2020-02-20 가톨릭대학교 산학협력단 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU3064397A (en) 1996-05-24 1997-12-09 Dow Chemical Company, The Process for preparing aliphatic ester compounds and alkanols
EA004403B1 (ru) * 1996-07-24 2004-04-29 Дюпон Фармасьютикалз Компани Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JP3621706B2 (ja) * 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
AU8181098A (en) 1997-07-03 1999-01-25 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
UA62972C2 (en) 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
ATE301657T1 (de) * 1998-01-28 2005-08-15 Bristol Myers Squibb Pharma Co Azolo-pyrimidine
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP2002510695A (ja) 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
NZ528207A (en) * 2001-03-13 2006-02-24 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Also Published As

Publication number Publication date
JP4549630B2 (ja) 2010-09-22
CA2440553A1 (en) 2002-09-19
US20040014760A1 (en) 2004-01-22
UA74634C2 (uk) 2006-01-16
DE60218434T2 (de) 2007-11-08
CY1106607T1 (el) 2012-01-25
AU2002245605B2 (en) 2006-02-02
HRP20030822B1 (en) 2008-01-31
BR0208357A (pt) 2004-06-29
KR20030080086A (ko) 2003-10-10
MY146935A (en) 2012-10-15
CA2440553C (en) 2010-06-08
NO20034023L (no) 2003-09-11
DK1368094T3 (da) 2007-07-02
IS6947A (is) 2003-09-10
IL157615A (en) 2009-09-01
NO20034023D0 (no) 2003-09-11
NO328580B1 (no) 2010-03-22
YU71503A (sh) 2006-05-25
US20080139567A1 (en) 2008-06-12
HU229317B1 (en) 2013-10-28
US20030125330A1 (en) 2003-07-03
TWI257388B (en) 2006-07-01
RU2292347C2 (ru) 2007-01-27
MXPA03008185A (es) 2004-01-29
HK1057182A1 (en) 2004-03-19
WO2002072202A1 (en) 2002-09-19
IS2839B (is) 2013-06-15
HUP0303480A3 (en) 2005-12-28
EP1368094A4 (en) 2004-03-31
DE60218434D1 (en) 2007-04-12
NZ528207A (en) 2006-02-24
PL368644A1 (en) 2005-04-04
HUP0303480A2 (hu) 2004-01-28
SK287603B6 (sk) 2011-03-04
KR100875595B1 (ko) 2008-12-23
SK11572003A3 (sk) 2004-02-03
EP1368094A1 (en) 2003-12-10
US7358252B2 (en) 2008-04-15
HRP20030822A2 (en) 2004-04-30
US7157578B2 (en) 2007-01-02
RU2003130093A (ru) 2005-03-20
US7662817B2 (en) 2010-02-16
US20070054913A1 (en) 2007-03-08
PT1368094E (pt) 2007-05-31
BG66331B1 (bg) 2013-06-28
BG108189A (bg) 2004-09-30
IL157615A0 (en) 2004-03-28
CN1509196A (zh) 2004-06-30
RS50863B (sr) 2010-08-31
PL208278B1 (pl) 2011-04-29
EP1368094B1 (en) 2007-02-28
JP2004530662A (ja) 2004-10-07
ES2282401T3 (es) 2007-10-16
CZ20032481A3 (cs) 2007-12-27
AR032986A1 (es) 2003-12-03
ZA200306995B (en) 2004-09-08
EE200300435A (et) 2003-12-15
GEP20053608B (en) 2005-09-12
ATE355102T1 (de) 2006-03-15
CN100427093C (zh) 2008-10-22

Similar Documents

Publication Publication Date Title
EE05433B1 (et) 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine
EE05223B1 (et) Triasoloprimidiini hendid, meetod nende valmistamiseks ning nende kasutamine
DK1242425T3 (da) N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)arylsulfonamid-forbindelser og deres anvendelse som herbicider
DK1625847T3 (da) Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
ATE284404T1 (de) Pyrazolo(4,3-d)pyrimidinderivate
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
EE200200506A (et) 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
EE200300347A (et) Aniliini derivaadid, mis on kasulikud kui fosfodiesteraas 4 inhibiitorid
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DK1250328T4 (da) Dihydro-1,3,5-triazindiaminderivater og terapeutisk anvendelse deraf
DE60205921D1 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
DE60127434D1 (de) Benzoxazinonderivative, deren herstellung und verwendung
ATE267201T1 (de) 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE60208044D1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60210696D1 (de) Optisch aktive 4-(tert-Butoxycarbonyl)piperazin Derivate und Verfahren zu ihrer Herstellung
PT1325010E (pt) 3, 4-di-hidropirimido [1,2-a] pirimidinas e 3, 4-di-hidropirazino [1,2-a] pirimidinas substituidas
FR2820135B1 (fr) Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation
AU2002346927A1 (en) 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20170306